The first case study, CZS-035, isa ligand for polo-likekinase 4 (PLK4) and a warhead component used to synthesize a therapeuticPROTAC for breast cancer treatment, discovered by Sun et al. (Figure A). Here, PLK4 is linked to breast carcinoma.